CSE Bulletin: New Listing - Pharmala Biotech Holdings Inc. (MDMA)
Toronto, Ontario--(Newsfile Corp. - le 10 janvier/January 2022) The common shares of Pharmala Biotech Holdings Inc. have been approved for listing on the CSE.
- Toronto, Ontario--(Newsfile Corp. - le 10 janvier/January 2022) The common shares of Pharmala Biotech Holdings Inc. have been approved for listing on the CSE.
- Pharmala is focused on manufacture of Active Pharmaceutical Ingredients, of the Substituted methylenedioxy- phenethylamines class (MDXX), including 3,4-Methylenedioxymethamphetamine (MDMA).
- Les actions ordinaires de Pharmala Biotech Holdings Inc. ont t approuves pour inscription sur le CSE.
- Pharmala se concentre sur la fabrication d'ingrdients pharmaceutiques actifs, de la classe des mthylnedioxyphnthylamines substitues ( MDXX ), y compris la 3,4-mthylnedioxymthamphtamine ( MDMA ).